losartan has been researched along with Epidermolysis Bullosa Dystrophica in 6 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Epidermolysis Bullosa Dystrophica: Form of epidermolysis bullosa characterized by atrophy of blistered areas, severe scarring, and nail changes. It is most often present at birth or in early infancy and occurs in both autosomal dominant and recessive forms. All forms of dystrophic epidermolysis bullosa result from mutations in COLLAGEN TYPE VII, a major component fibrils of BASEMENT MEMBRANE and EPIDERMIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of losartan in the prevention of restenosis after BD of esophageal stenosis in children with DEB." | 8.31 | Our experience of using Losartan for esophageal stenosis in children with dystrophic form of congenital epidermolysis bullosa. ( Abaykhanov, R; Budkina, T; Dyakonova, E; Fisenko, A; Gusev, A; Lokhmatov, M; Murashkin, N; Oldakovskiy, V; Tupylenko, A; Yatzik, S, 2023) |
| "To evaluate the efficacy of losartan in the prevention of restenosis after BD of esophageal stenosis in children with DEB." | 4.31 | Our experience of using Losartan for esophageal stenosis in children with dystrophic form of congenital epidermolysis bullosa. ( Abaykhanov, R; Budkina, T; Dyakonova, E; Fisenko, A; Gusev, A; Lokhmatov, M; Murashkin, N; Oldakovskiy, V; Tupylenko, A; Yatzik, S, 2023) |
| "The scarring is driven by inflammatory processes, particularly the TGF-β signaling pathways, resulting in excess synthesis and deposition of the extracellular matrix, especially collagen." | 1.72 | Losartan treatment improves recessive dystrophic epidermolysis bullosa: A case series. ( Abdollahimajd, F; Hajimoradi, B; Mansouri, P; Pourani, MR; Rakhshan, A; Uitto, J; Vahidnezhad, H; Youssefian, L, 2022) |
| "A 6-year-old child with recessive dystrophic epidermolysis bullosa, confirmed by history, clinical exam, and antigen mapping, was treated with losartan with reduction in the blistering and better quality of life." | 1.56 | Losartan as disease modulating therapy for recessive dystrophic epidermolysis bullosa. ( Inamadar, AC, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 5 (83.33) | 2.80 |
| Authors | Studies |
|---|---|
| Pourani, MR | 1 |
| Vahidnezhad, H | 2 |
| Mansouri, P | 1 |
| Youssefian, L | 1 |
| Rakhshan, A | 1 |
| Hajimoradi, B | 1 |
| Abdollahimajd, F | 1 |
| Uitto, J | 2 |
| Relvas, M | 1 |
| Figueiredo, AC | 1 |
| Calado, R | 1 |
| Calvão, J | 1 |
| Ramos, L | 1 |
| Oldakovskiy, V | 1 |
| Murashkin, N | 1 |
| Lokhmatov, M | 1 |
| Gusev, A | 1 |
| Tupylenko, A | 1 |
| Budkina, T | 1 |
| Yatzik, S | 1 |
| Dyakonova, E | 1 |
| Abaykhanov, R | 1 |
| Fisenko, A | 1 |
| Inamadar, AC | 1 |
| Nyström, A | 1 |
| Thriene, K | 1 |
| Mittapalli, V | 1 |
| Kern, JS | 1 |
| Kiritsi, D | 1 |
| Dengjel, J | 1 |
| Bruckner-Tuderman, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Computational Drug Repurposing for All Epidermolysis Bullosa Simplex (EBS) Cases[NCT03269474] | 60 participants (Anticipated) | Observational | 2017-11-28 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for losartan and Epidermolysis Bullosa Dystrophica
| Article | Year |
|---|---|
Losartan treatment improves recessive dystrophic epidermolysis bullosa: A case series.
Topics: Animals; Cicatrix; Collagen; Collagen Type VII; Epidermolysis Bullosa Dystrophica; Female; Losartan; | 2022 |
Losartan as therapy for recessive dystrophic epidermolysis bullosa: Report of three cases.
Topics: Epidermolysis Bullosa; Epidermolysis Bullosa Dystrophica; Humans; Losartan; Skin | 2022 |
Our experience of using Losartan for esophageal stenosis in children with dystrophic form of congenital epidermolysis bullosa.
Topics: Adolescent; Child; Child, Preschool; Constriction, Pathologic; Epidermolysis Bullosa; Epidermolysis | 2023 |
Losartan as disease modulating therapy for recessive dystrophic epidermolysis bullosa.
Topics: Child; Epidermolysis Bullosa Dystrophica; Humans; Losartan; Quality of Life | 2020 |
Losartan for treatment of epidermolysis bullosa: A new perspective.
Topics: Epidermolysis Bullosa; Epidermolysis Bullosa Dystrophica; Humans; Losartan | 2021 |
Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms.
Topics: Animals; Disease Models, Animal; Epidermolysis Bullosa Dystrophica; Immunologic Factors; Inflammatio | 2015 |